Investigation of the Roles of Toxin-Coregulated Pili and Mannose-Sensitive Hemagglutinin Pili in the Pathogenesis of Vibrio cholerae O139 Infection (original) (raw)

Abstract

In this study, adult volunteers were fed tcpA and mshA deletion mutants of V. cholerae O139 strain CVD 112 to determine the role of toxin-coregulated pili (TCP) and mannose-sensitive hemagglutinin (MSHA) in intestinal colonization. Eight of 10 volunteers who received CVD 112 or CVD 112 Δ_mshA_ shed the vaccine strains in their stools; the geometric mean peak excretion for both groups was 1.4 × 105 CFU/g of stool. In contrast, only one of nine recipients of CVD 112 Δ_tcpA_ shed vibrios in his stool (P < 0.01); during the first 24 h after inoculation, 3 × 102 CFU/g was recovered from this volunteer. All recipients of CVD 112 and 8 (80%) of the recipients of CVD 112 Δ_mshA_ developed at least a fourfold rise in vibriocidal titer after immunization. In contrast, only one (11%) of the nine recipients of CVD 112 Δ_tcpA_ developed a fourfold rise in vibriocidal titer (P < 0.01). We conclude that TCP are an important colonization factor of V. cholerae O139 and probably of El Tor V. cholerae O1. In contrast, MSHA does not appear to promote intestinal colonization in humans.

Adherence of Vibrio cholerae to the intestinal mucosa might be mediated by different mechanisms, depending on the biotype (classical or El Tor) and serotype (O1 and O139). It is clear that colonization of strains of V. cholerae O1 of the classical biotype is mediated by toxin-coregulated pili (TCP), which are encoded by tcpA (20). The importance of TCP in the pathogenesis of cholera was demonstrated in volunteer studies. Classical Ogawa V. cholerae O1 strain 395 with deletions in tcpA did not cause diarrhea, did not colonize the duodenal fluids or stools of volunteers, and did not induce vibriocidal or antitoxic immune responses (6, 7).

The tcpA gene is also present in El Tor biotype V. cholerae O1 strains (9, 16). In addition, most, if not all, strains of El Tor V. cholerae O1 express another pilus, called mannose-sensitive hemagglutinin (MSHA) (10). Mutations in tcpA and mshA have been constructed, and the strains have been studied with infant mice. The colonization of the _mshA_-deleted El Tor V. cholerae O1 strain was no different from that of the wild type; in contrast, the El Tor strain with deletions in tcpA was markedly reduced in its ability to colonize infant mice (1, 2, 21).

The roles of these two pili in mediating protective immunity have been studied with animals. Antibodies against classical TCP have provided variable protection against V. cholerae El Tor in mice (1, 15, 17, 18, 22). The inconsistent protection of anti-TCP antibodies is likely explained by the sequence differences between El Tor and classical TCP; these proteins show 82% identity (16). The differences in protection mediated by TCP antibodies may be due to the difference in the specificities of anti-classical TCP serum and anti-El Tor TCP serum.

The mechanism of colonization of V. cholerae O139 has not been established. V. cholerae O139 strains are closely related to El Tor strains of the O1 group (3, 5, 8, 23), so one might expect that colonization factors of El Tor O1 strains would also be important in O139 strains. The gene for TCP pilin is present in O139 strains, and the amino acid sequence is identical to that of El Tor O1 strains (16). Mutants of V. cholerae O139 strain M03 with deletions in tcpA and mshA have been constructed; in colonization competition studies with the wild type, the tcpA deletion mutant was markedly decreased in colonization (21). In contrast, the Δ_mshA_ mutant was somewhat better able to compete for colonization of mice. In an independent study, an O139 strain with deletions in mshA had no competitive advantage (1). These data suggest that TCP are essential for the colonization of infant mice with V. cholerae O139 and that MSHA does not appear to have a significant role.

The purpose of this study was to determine the role of tcpA and mshA in the intestinal colonization of volunteers given V. cholerae O139 vaccine strain CVD 112 modified by deletions in tcpA and mshA (designated strains KHT47 and KHT37, respectively). CVD 112 is a derivative of V. cholerae O139 strain AI1837, designed as a vaccine candidate by deletions in genes for cholera toxin A subunit (ctxA), zonula occludens toxin, accessory cholera enterotoxin, and core encoded pilin, which are on the bacteriophage CTXΦ (24). In the volunteer study described here, we chose to use CVD 112 to avoid the risks of dehydrating diarrhea in volunteers while still addressing questions about colonization.

MATERIALS AND METHODS

Clinical study design.

Healthy adult volunteers were educated about cholera and the requirements of the protocol, and informed, written consent was obtained from each volunteer. Prospective volunteers were carefully screened to ensure that they were in excellent physical and mental health. Screening consisted of a medical history, physical examination, interview by a clinical psychologist, and a battery of blood tests.

A group of 29 inpatient volunteers was admitted to the research isolation ward, located in the University of Maryland Hospital. They were randomized to receive the following with sodium bicarbonate buffer: (i) 1 × 107 to 2 × 107 CFU of V. cholerae O139 vaccine strain CVD 112 (n = 10), (ii) 1 × 107 to 2 × 107 CFU of V. cholerae O139 strain CVD 112 Δ_tcpA_ (designated KHT47) (n = 9), or (iii) 1 × 107 to 2 × 107 CFU of V. cholerae O139 strain CVD 112 Δ_mshA_ (designated KHT37) (n = 10).

Daily clinical observations were made in which symptoms were recorded. Volunteers who developed diarrhea were given oral rehydration (with World Health Organization glucose-electrolyte solution) after each loose stool. Volunteers were observed for 4 days and then treated with tetracycline (500 mg orally every 6 h for four doses), followed by a single oral dose of doxycycline. They were discharged from the isolation ward at day 7 after ingestion of vibrios.

From the time of admission, volunteers collected every bowel movement in plastic containers. After collection of a stool, the contents of the stool container were inspected and graded for consistency of the stool according to five grades: grade 1, firm; grade 2, soft; grade 3, thick liquid; grade 4, opaque watery; and grade 5, rice water. Grades 1 and 2 are variations of normal stools, while grades 3 to 5 are considered abnormal.

To culture vibrio from the proximal small intestine (the critical site of host-bacterium interaction), volunteers ingested gelatin-encapsulated string devices (Enterotest) approximately 20 and 44 h after ingestion of V. cholerae as previously described (7). Blood was collected before and 11 and 28 days after ingestion of vibrio for measurements of vibriocidal and anti-cholera toxin and anti-TCP antibodies.

Preparation and administration of strains CVD 112, KHT47, and KHT37.

KHT47 and KHT37 were constructed as previously described (21). The strains have no growth defect as determined by in vitro growth competition studies with their _lacZ_-negative parent (21). The mutant strains and CVD 112 agglutinated with anti-O139 antiserum to the same extent. The motilities of CVD 112, KHT37, and KHT47 were normal and equivalent as assessed by motility agar plates (Luria-Bertani agar containing 0.3% agar). The preparation of inocula for administration to volunteers has been previously described (19). The strains were administered orally with NaHCO3. Two grams of NaHCO3 was dissolved in 5 oz (150 ml) of distilled water. Volunteers drank 4 oz of the NaHCO3 solution; 1 min later, they ingested the vibrio strain suspended in the remaining 1 oz of NaHCO3 water. Volunteers had nothing to eat or drink for 90 min before and after vaccination.

Definition of diarrhea.

Diarrhea was defined as the passage of two or more unformed (grades 3 to 5) stools over a 48-h period that equaled or exceeded 200 g or a single voluminous stool if it totaled 300 g or greater.

Bacteriology.

All stools were plated directly onto thiosulfate-citrate-bile salts-sucrose (TCBS) agar as well as inoculated into alkaline peptone water enrichment broth for overnight incubation before being plated onto TCBS. Suspicious colonies were agglutinated with specific antiserum. Up to three stools each day were cultured quantitatively to determine the number of vibrios per gram of stool.

Duodenal strings were tweezed with a sterile gloved hand to express duodenal fluid. This was quantitatively cultured as described above as well as inoculated directly onto TCBS. In addition, the strings were inoculated into alkaline peptone water for overnight incubation before inoculation of plates of TCBS agar.

Immunology.

Serum vibriocidal responses were determined against strain 2L, the unencapsulated mutant of AI1837, the parent strain of CVD 112 (13). Immunoglobulin G (IgG) antitoxin antibodies were measured by previously described methods (12). TCP antibodies were also measured by enzyme-linked immunosorbent assay as described previously (6) with purified TCP (18).

Statistical analysis.

Rates of diarrhea and antibody conversion were compared by Fisher’s exact tests. Comparisons of antibody titers were performed on log-transformed reciprocal titers by Student’s t test.

RESULTS

Clinical and bacteriologic results.

Mild diarrhea occurred in 3 (30%) of 10 recipients of 107 CFU of CVD 112, 5 (50%) of 10 recipients of 107 CFU of CVD 112 Δ_mshA_, and in none of 9 recipients of 107 CFU of CVD 112 Δ_tcpA_ (Table 1). These rates of diarrhea among recipients of CVD 112 and CVD 112 Δ_mshA_ were similar to those previously observed among recipients of similar doses of CVD 112 (24).

TABLE 1.

Clinical and bacteriologic responses in volunteers who received 107 CFU of V. cholerae O139 strain CVD 112, KHT37 (CVD 112 Δ_mshA_), or KHT47 (CVD 112 Δ_tcpA_)

Strain Diarrhea attack ratea (%) Mean diarrheal stool vol (ml) Ratea of vibrio excretion (%) Geometric mean peak no. of organisms/g of stool Ratea of positive duodenal fluid cultures (%) Geometric mean no. of organisms recovered from duodenal fluid
CVD 112 3/10 (30) 693 8/10 (80) 1.4 × 105 3/8 (38) 1.6 × 103
KHT 37 (CVD 112 Δ_mshA_) 5/10 (50) 529 8/10 (80) 1.4 × 105 2/9 (22) 3.6 × 103
KHT47 (CVD 112 Δ_tcpA_) 0/9 (0)b 0 1/9 (11)c 3 × 102 0/7 (0)d 0

Eight of 10 volunteers who received CVD 112 or CVD 112 Δ_mshA_ shed the vaccine strains in their stools; the geometric mean peak excretion for both groups was 1.4 × 105 CFU/g of stool (Table 1). This rate of shedding is similar to that observed after ingestion of the wild-type parent strain, AI1837 (19). In contrast, only one of nine recipients of CVD 112 Δ_tcpA_ shed vibrios in his stool (P < 0.01); during only the first 24 h after inoculation, 3 × 102 CFU/g was recovered from this volunteer. The duodenal fluid cultures gave a similar pattern (Table 1). The numbers of organisms recovered from intestinal fluid were similar in recipients of CVD 112 and CVD 112 Δ_mshA_ (1.6 × 103 and 3.6 × 103, respectively).

Immune responses.

V. cholerae O139 stimulates meager titers of vibriocidal antibodies after wild-type infection, compared to the titers stimulated by V. cholerae O1, probably due to the presence of the capsule on O139 strains (13, 14). All recipients of CVD 112 and eight (80%) of the recipients of CVD 112 Δ_mshA_ developed a fourfold or greater rise in vibriocidal titer after immunization; the geometric mean peak reciprocal titers were 121 and 106, respectively (Table 2). In contrast, only one (11%) of the nine recipients of CVD 112 Δ_tcpA_ developed a fourfold rise in vibriocidal titer (P < 0.01, Student’s t tests comparing CVD 112 Δ_tcpA_ responses to CVD 112 and CVD 112 Δ_mshA_ responses). This volunteer was the one who shed small numbers of CVD 112 Δ_tcpA_ in his stool for 1 day. The vibriocidal response in this volunteer was unusual, since it occurred on day 28 after vaccination and was not present on day 11 after vaccination, when the amount of vibriocidal antibody in U.S. volunteers usually peaks (4). None of the recipients of CVD 112 Δ_tcpA_ developed anti-cholera toxin antibody, while all of the recipients of CVD 112 and 80% of the recipients of CVD 112 Δ_mshA_ developed anti-cholera toxin antibody (P < 0.001, Fisher’s exact tests, comparing CVD 112 Δ_tcpA_ to either of the other two groups). IgG antibodies against TCP were detected in 2 of 10 recipients of CVD 112, 1 of 10 recipients of CVD 112 Δ_mshA_, and none of the recipients of CVD 112 Δ_tcpA._

TABLE 2.

Immune responses in volunteers who received 107 CFU of V. cholerae O139 strain CVD 112, KHT37 (CVD 112 Δ_mshA_), or KHT47 (CVD 112 Δ_tcpA_)

Strain Vibriocidala antibody seroconversion rateb (%) Geometric mean peak reciprocal vibriocidal antibody titer IgG anti-cholera toxin antibody seroconver- sion rateb (%) Geometric mean change in optical density for IgG anticholera toxin antibody IgG anti-TCP antibody seroconversion rateb (%)
CVD 112 10/10 (100) 121 10/10 (100) 0.78 2/10 (20)
KHT37 (CVD 112 Δ_mshA_) 8/10 (80) 106 8/10 (80) 0.63 1/10 (10)
KHT47 (CVD 112 Δ_tcpA_) 1/9 (11)c 29d 0/9 (0)e 0.04 0/9 (0)

DISCUSSION

This clinical study clearly demonstrates the importance of TCP expression for V. cholerae O139 to colonize the intestine, cause diarrhea, and stimulate immune responses. Deletion in tcpA resulted in the absence of diarrhea and marked decrease in colonization and immune responses in volunteers. Deletion in mshA had no effect on the attack rate of diarrhea, the volume of diarrheal stool, or the numbers of vibrios recovered in duodenal fluid or stool. Our data suggest that MSHA is not necessary for colonization, and a role for MSHA in producing mild diarrhea associated with CVD 112 could not be demonstrated.

V. cholerae O139 is strikingly similar to biotype El Tor V. cholerae O1 and probably evolved recently from an El Tor strain (3, 5, 8). Although O139 strains express a polysaccharide capsule and have an altered lipopolysaccharide, they are similar to El Tor O1 strains by DNA sequences of crucial virulence factors and by multilocus enzyme electrophoresis. It is likely, therefore, that TCP are the critical colonization factor for El Tor O1, as they are for classical O1 strains (7).

This study emphasizes the importance of colonization for stimulating an immune response to V. cholerae. This finding has implications for the development of live attenuated vaccine strains, which should express TCP, and killed-whole-cell vaccines, which should contain TCP on the surfaces of classical and El Tor components, to stimulate protective immune responses. The very low (11%) vibriocidal seroconversion rate among recipients of KHT47 (Δ_tcpA_) demonstrates that V. cholerae must express this antigen to stimulate serum vibriocidal antibodies, the best immune correlate of protection against cholera. These data also support the possibility that in humans, like in animals, strong mucosal immunity against the single antigen TCP could be adequate for protection against cholera by interfering with colonization and diarrheagenicity. Protection against another toxigenic enteric pathogen, Escherichia coli, appears to be mediated by anti-colonization factor responses (11). However, unlike E. coli colonization factors, TCP are only weakly immunogenic in humans after infection with live V. cholerae O1 (6) and after vaccination with O139 strain CVD 112, and so anti-TCP responses do not participate in natural immunity. It is possible that an immune response to TCP could be stimulated by presenting this antigen to mucosal immune sites with an appropriate carrier or with a mucosal adjuvant.

TCP have another function in bacterial physiology: the pilus is the receptor for a filamentous bacteriophage, CTXΦ, which encodes V. cholerae toxins (24). This surface structure, then, is possibly the ultimate virulence factor of V. cholerae, since TCP mediate infection of the bacterium with the phage, which in turn encodes cholera toxin, the factor responsible for cholera gravis. Our study shows that, without TCP, V. cholerae is thoroughly disarmed.

ACKNOWLEDGMENTS

This study was supported by National Institutes of Health contract NO1 AI-65299 to C.O.T. and by AI-25096 to R.K.T.

We acknowledge the excellent clinical care provided by the Center for Vaccine Development nursing staff. We are indebted to Kathy Palmer for excellent research coordination.

REFERENCES